Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder.
Mandelkow T, Blessin NC, Lueerss E, Pott L, Simon R, Li W, Wellge B, Debatin NF, Höflmayer D, Izbicki JR, Büscheck F, Luebke AM, Wittmer C, Jacobsen F, Lutz F, Burandt E, Steurer S, Sauter G, Tsourlakis MC, Wilczak W, Hinsch A, Minner S. Mandelkow T, et al. Among authors: wittmer c. Dis Markers. 2019 May 2;2019:2532518. doi: 10.1155/2019/2532518. eCollection 2019. Dis Markers. 2019. PMID: 31191745 Free PMC article.
Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.
Li W, Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Pott L, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt E, Steurer S, Wilczak W, Hinsch A. Li W, et al. Among authors: wittmer c. BMC Cancer. 2018 Dec 4;18(1):1209. doi: 10.1186/s12885-018-5111-1. BMC Cancer. 2018. PMID: 30514251 Free PMC article.
Patterns of TIGIT Expression in Lymphatic Tissue, Inflammation, and Cancer.
Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Li W, Makrypidi-Fraune G, Wellge B, Mandelkow T, Debatin NF, Höflmayer D, Lennartz M, Sauter G, Izbicki JR, Minner S, Büscheck F, Uhlig R, Dum D, Krech T, Luebke AM, Wittmer C, Jacobsen F, Burandt EC, Steurer S, Wilczak W, Hinsch A. Blessin NC, et al. Among authors: wittmer c. Dis Markers. 2019 Jan 10;2019:5160565. doi: 10.1155/2019/5160565. eCollection 2019. Dis Markers. 2019. PMID: 30733837 Free PMC article.
Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
Burdelski C, Barreau Y, Simon R, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Sauter G, Wittmer C, Steurer S, Adam M, Huland H, Schlomm T, Tsourlakis MC, Quaas A. Burdelski C, et al. Among authors: wittmer c. Hum Pathol. 2015 Apr;46(4):514-23. doi: 10.1016/j.humpath.2014.06.006. Epub 2014 Jun 26. Hum Pathol. 2015. PMID: 25701228
HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.
Burdelski C, Ruge OM, Melling N, Koop C, Simon R, Steurer S, Sauter G, Kluth M, Hube-Magg C, Minner S, Wittmer C, Wilczak W, Hinsch A, Lebok P, Izbicki JR, Heinzer H, Graefen M, Huland H, Schlomm T, Krech T. Burdelski C, et al. Among authors: wittmer c. Exp Mol Pathol. 2015 Jun;98(3):419-26. doi: 10.1016/j.yexmp.2015.03.024. Epub 2015 Mar 18. Exp Mol Pathol. 2015. PMID: 25794974
VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy.
Tsourlakis MC, Khosrawi P, Weigand P, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Krech T, Wilczak W, Huland H, Simon R, Schlomm T, Steurer S. Tsourlakis MC, et al. Among authors: wittmer c. Int J Mol Sci. 2015 Apr 16;16(4):8591-606. doi: 10.3390/ijms16048591. Int J Mol Sci. 2015. PMID: 25894226 Free PMC article.
Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer.
Burdelski C, Reiswich V, Hube-Magg C, Kluth M, Minner S, Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wittmer C, Huland H, Simon R, Schlomm T, Sauter G, Steurer S. Burdelski C, et al. Among authors: wittmer c. Clin Cancer Res. 2015 Aug 1;21(15):3471-9. doi: 10.1158/1078-0432.CCR-14-0620. Epub 2015 Apr 29. Clin Cancer Res. 2015. PMID: 25925890
Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers.
Burdelski C, Bujupi E, Tsourlakis MC, Hube-Magg C, Kluth M, Melling N, Lebok P, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Wilczak W, Simon R, Schlomm T, Steurer S, Krech T. Burdelski C, et al. Among authors: wittmer c. PLoS One. 2015 Jun 1;10(6):e0128525. doi: 10.1371/journal.pone.0128525. eCollection 2015. PLoS One. 2015. PMID: 26030748 Free PMC article.
High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer.
Melling N, Harutyunyan L, Hube-Magg C, Kluth M, Simon R, Lebok P, Minner S, Tsourlakis MC, Koop C, Graefen M, Adam M, Haese A, Wittmer C, Steurer S, Izbicki J, Sauter G, Wilczak W, Schlomm T, Krech T. Melling N, et al. Among authors: wittmer c. PLoS One. 2015 Jul 31;10(7):e0134614. doi: 10.1371/journal.pone.0134614. eCollection 2015. PLoS One. 2015. PMID: 26230842 Free PMC article.
Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N, Thomsen E, Tsourlakis MC, Kluth M, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Wittmer C, Sauter G, Wilczak W, Huland H, Simon R, Schlomm T, Steurer S, Krech T. Melling N, et al. Among authors: wittmer c. Carcinogenesis. 2015 Nov;36(11):1333-40. doi: 10.1093/carcin/bgv137. Epub 2015 Sep 21. Carcinogenesis. 2015. PMID: 26392259
83 results